Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07317154 · ClinicalTrials.gov registry record · Phase 1
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
A Phase 1 study of Recurrent Respiratory Papillomatosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT07317154: Recruiting Phase 1 study of Recurrent Respiratory Papillomatosis, sponsored by Mayo Clinic.
NCT07317154 is a Phase 1 study of Recurrent Respiratory Papillomatosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 37-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07317154, a Phase 1 study of Recurrent Respiratory Papillomatosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Primary Outcome
Safety will be assessed as number of participants to experience adverse events, including systemic symptoms, irritation, inflammation, and any adverse events identified through physical exam and blood counts.
Conditions Studied
Interventions
- BIOLOGICAL Immunotherapy
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-01 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT07317154 shows while recruiting
NCT07317154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 37-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy is the first listed.
NCT07317154 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07317154 about?
NCT07317154 is a clinical study titled "Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients". The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
What is the current status of trial NCT07317154?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-01. Estimated completion is 2027-02.
What conditions does trial NCT07317154 study?
This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis.
What interventions are being tested in trial NCT07317154?
The interventions under investigation include: Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT07317154?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07317154 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Respiratory Papillomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
ACTIVE NOT RECRUITING · Phase 1
-
Zopa Retreatment and Vector Shedding in Adults With RRP
RECRUITING · Phase 4
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
RECRUITING
-
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia